ReviewMolecules (Basel, Switzerland)2009
Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.
Review in Molecules (Basel, Switzerland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Recent Advances in the Synthesis of Acyclic Nucleosides and Their Therapeutic Applications.Topics in current chemistry (Cham) · 2024Review
- The hypoxia-adenosine link during inflammation.Journal of applied physiology (Bethesda, Md. : 1985) · 2017Review
- Effective Synthesis of Nucleosides Utilizing O-Acetyl-Glycosyl Chlorides as Glycosyl Donors in the Absence of Catalyst: Mechanism Revision and Application to Silyl-Hilbert-Johnson Reaction.Molecules (Basel, Switzerland) · 2017Article
- Immune Thrombocytopenic Purpura During Maintenance Phase of Acute Lymphoblastic Leukemia: A Rare Coexistence Requiring a High Degree of Suspicion, a Case Report and Review of the Literature.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2015Review
- 2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models.Molecular imaging and biology · 2014Article
- 2,6-Di-chloro-9-(2',3',5'-tri-O-acetyl-β-d-ribo-furanos-yl)-9H-purine.Acta crystallographica. Section E, Structure reports online · 2014Article
- Intrinsic apoptosis pathway in fallopian tube epithelial cells induced by cladribine.TheScientificWorldJournal · 2014Article
- Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovarian surface epithelial cells of cladribine-treated rats.Protoplasma · 2013Article
- French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia.Experimental hematology & oncology · 2012Article
- Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents.Molecules (Basel, Switzerland) · 2011Review
- Synthesis and cytotoxic activity of some new 2,6-substituted purines.Molecules (Basel, Switzerland) · 2011Article
- Modulators of nucleoside metabolism in the therapy of brain diseases.Current topics in medicinal chemistry · 2011Review
- Deconstructing nucleotide binding activity of the Mdm2 RING domain.Nucleic acids research · 2010Article
- The effects of forodesine in murine and human multiple myeloma cells.Advances in hematology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (PNAs) plays an important role. Three of them: pentostatin (DCF), cladribine (2-CdA) and fludarabine (FA) were approved by Food and Drug Administration (FDA) for the treatment of hematological malignancies. Recently three novel PNAs: clofarabine (CAFdA), nelarabine (ara-G) and forodesine (immucillin H, BCX-1777) have been synthesized and introduced into preclinical studies and clinical trials. These agents seem to be useful mainly for the treatment of human T-cell proliferative disorders and they are currently undergoing clinical trials in lymphoid malignancies. However, there are also several studies suggesting the role of these drugs in B-cell malignancies. This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.